Novartis Sued Over 'Virus Production' Patent For Flu Shots

Law360, New York (January 6, 2014, 8:17 PM EST) -- A Novartis AG unit ripped off a Canadian company's patented process for increasing virus production and using it to make a flu vaccine, according to a suit filed in Texas federal court Monday.

Microbix Biosystems Inc. alleges that Switzerland-based Novartis Vaccines and Diagnostics Inc. misappropriated Microbix's methodology for upping virus yields during the manufacturing of vaccines and unlawfully relied on it to produce Novartis' Agriflu.

“VirusMax is a novel technology that was developed by our company at significant cost," Vaughn Embro-Pantalony, president and CEO of Microbix,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.